ASX - Biostache

Recent Articles..

To The Moon: Our Interview With ResearchSat
Recently, I had the chance to sit down and chat with ResearchSat’s founder/CEO RaviTeja Duggineni and their head of investor relations, Rahul Kundnani.
The Might of Mesoblast: How Perseverance Paid Off
Last year, Mesoblast Ltd had their therapeutic RYONCIL approved by the FDA. This article touches on the journey to get to this milestone.
Who needs a heartbeat? BiVACOR The New Artificial Titanium Heart
Heart disease remains one of the leading causes of death globally, BiVACOR may be the solution to this – a total artificial heart that utilises a single motor with MAGLEV technology to pump blood to the lungs and body.
The Micro Apocalypse: Antimicrobial Resistance
Antibiotics are arguably one of the most important biotechnological inventions of the last century. Access to effective antibiotic and antimicrobial drugs has saved countless lives, and allowed for advancements in healthcare, increasing the success of other medical interventions such as surgery and chemotherapy.
Here’s why last week’s stock market crash is a warning sign for Australia’s biotech sector
Investments in biotechnology are most impactful when made by those with deep pockets. The aim of the game is to make a return on investment, …
Read more "Here’s why last week’s stock market crash is a warning sign for Australia’s biotech sector"

The Might of Mesoblast: How Perseverance Paid Off

by Harry GlaspoleASX, Drug Development, Finance January 14, 2025January 14, 2025No Comments

Last year, Mesoblast Ltd had their therapeutic RYONCIL approved by the FDA. This article touches on the journey to get to this milestone.

Here’s why last week’s stock market crash is a warning sign for Australia’s biotech sector

by Harry GlaspoleASX, Drug Development, Finance August 13, 2024August 13, 2024No Comments

Investments in biotechnology are most impactful when made by those with deep pockets. The aim of the game is to make a return on investment, which can only occur when biotech companies can create a profitable product. Without funding from angel investors/venture capitalists, many biotech companies cannot continue to meaningfully function. Analysis of the recent …

Read more “Here’s why last week’s stock market crash is a warning sign for Australia’s biotech sector”

Big day for Aussie biotech: NSB and MSB soar

by Harry GlaspoleASX, Biotechnology, Finance April 2, 2024April 3, 2024No Comments

Two Australian stock exchange listed biotech companies, Neuroscientific Biopharmaceuticals LTD and Mesoblast LTD, have experienced upward spikes in share price as a result of positive news released over the Easter holiday.